La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Pliant Therapeutics Gestione
Gestione criteri di controllo 2/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Bernard Coulie
Amministratore delegato
US$11.2m
Compenso totale
| Percentuale dello stipendio del CEO | 5.5% |
| Mandato del CEO | 8.5yrs |
| Proprietà del CEO | 1.1% |
| Durata media del management | 8.4yrs |
| Durata media del Consiglio di amministrazione | 6.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?
Jun 07
Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?
Feb 27Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?
Jul 21Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?
Mar 13Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?
Sep 10Pliant Therapeutics: Wait For A Better Price To Get In
Aug 20Pliant Therapeutics GAAP EPS of -$0.82 misses by $0.01, revenue of $4.99M
Aug 08Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?
Jul 28Pliant's PLN-74809 gets FDA fast track status for liver disease
Jul 21Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals
Jul 11Pliant: Major Catalyst Expected Beginning Of 2023
Jun 03We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate
Apr 22Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation
Dec 29We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth
Sep 07Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%
May 17Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
May 13Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans
Mar 22We're Not So Sure You Should Rely on Pliant Therapeutics's (NASDAQ:PLRX) Statutory Earnings
Jan 21
Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$185m |
| Mar 31 2024 | n/a | n/a | -US$171m |
| Dec 31 2023 | US$11m | US$610k | -US$161m |
| Sep 30 2023 | n/a | n/a | -US$155m |
| Jun 30 2023 | n/a | n/a | -US$144m |
| Mar 31 2023 | n/a | n/a | -US$133m |
| Dec 31 2022 | US$11m | US$587k | -US$123m |
| Sep 30 2022 | n/a | n/a | -US$113m |
| Jun 30 2022 | n/a | n/a | -US$109m |
| Mar 31 2022 | n/a | n/a | -US$103m |
| Dec 31 2021 | US$5m | US$556k | -US$97m |
| Sep 30 2021 | n/a | n/a | -US$92m |
| Jun 30 2021 | n/a | n/a | -US$81m |
| Mar 31 2021 | n/a | n/a | -US$75m |
| Dec 31 2020 | US$2m | US$499k | -US$42m |
| Sep 30 2020 | n/a | n/a | US$18m |
| Jun 30 2020 | n/a | n/a | US$19m |
| Mar 31 2020 | n/a | n/a | US$20m |
| Dec 31 2019 | US$2m | US$428k | -US$7m |
Compensazione vs Mercato: La retribuzione totale di Bernard ($USD 11.17M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 3.30M ).
Compensazione vs guadagni: La retribuzione di Bernard è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Bernard Coulie (57 yo)
8.5yrs
Mandato
US$11,165,999
Compensazione
Dr. Bernard Coulie, Ph D, M.D. M.B.A. is Director of Septerna, Inc. from February 2024. He serves as Independent Director at SQZ Biotechnologies Company since July 2021 and serves as its Independent Chairm...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | no data | US$11.17m | 1.1% $ 9.0m | |
| Chief Financial Officer | 5.7yrs | US$4.44m | 0.31% $ 2.6m | |
| General Counsel & Corporate Secretary | 3.8yrs | US$3.32m | 0.060% $ 491.5k | |
| Chief Business Officer | 8.4yrs | US$4.36m | 0.32% $ 2.6m | |
| Chief Medical Officer | 6.3yrs | US$4.69m | 0.22% $ 1.8m | |
| Scientific Founder & Member of Scientific Advisory Board | 9.6yrs | Nessun dato | Nessun dato | |
| Scientific Founder & Member of Scientific Advisory Board | 9.6yrs | Nessun dato | Nessun dato | |
| Scientific Founder & Member of Scientific Advisory Board | 9.6yrs | Nessun dato | Nessun dato | |
| Scientific Founder & Member of Scientific Advisory Board | 9.6yrs | Nessun dato | Nessun dato | |
| Interim Chief Technology Officer | no data | Nessun dato | Nessun dato | |
| Vice President of Investor Relations & Corporate Communications | no data | Nessun dato | Nessun dato | |
| Chief Human Resources Officer | 1.6yrs | Nessun dato | 0.0013% $ 10.7k |
8.4yrs
Durata media
51yo
Età media
Gestione esperta: Il team dirigenziale di PLRX è esperto e expertise (durata media dell'incarico 8.4 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 8.5yrs | US$11.17m | 1.1% $ 9.0m | |
| Scientific Founder & Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Scientific Founder & Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Scientific Founder & Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Scientific Founder & Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 4.7yrs | US$278.71k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 8.1yrs | US$277.21k | 0.058% $ 471.9k | |
| Independent Director | 7yrs | US$271.96k | 0.048% $ 393.8k | |
| Independent Chairman | 6.7yrs | US$296.71k | 0.16% $ 1.3m | |
| Independent Director | 5.4yrs | US$277.96k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato |
6.8yrs
Durata media
61yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PLRX sono considerati esperti (durata media dell'incarico 6.8 anni).